The executive director of the Lead (Leaders Engaged on Alzheimer’s Disease) Coalition provided thoughts on the journey and lessons learned from aducanumab (Aduhelm) following Biogen’s decision to remove it from market. [WATCH TIME: 8 minutes]
Ian Kremer
Advertisement
Ian Kremer is executive director of the LEAD Coalition.
Articles by Ian Kremer
The executive director of the LEAD Coalition calls for greater collaboration and support from government and the healthcare community in order to boost health equity.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Anti-MTBR Tau Antibody Etalanetug Given FDA Fast Track Designation
2
FDA Fast Tracks Etalanetug, Encouraging Interim TEMPO-4 Data, Initial Data on Cell Therapy UX-DA001
3
NeurologyLive® Friday 5 — October 24, 2025
4
Incidence and Prevalence of Frontotemporal Dementia Similar to Dementia with Lewy Bodies, Meta-Analysis Shows
5
